EP Patent

EP2833878A1 — Local composition to treat stress urinary incontinence in a female subject

Assigned to TIXUPHARMA · Expires 2015-02-11 · 11y expired

What this patent protects

The invention refers to compositions comprising spermidine for the treatment of the stress urinary incontinence in a female subject. The inventive compositions are conceived either for transvaginal application to release spermidine onto external sphincter, urethra and endopelvic …

USPTO Abstract

The invention refers to compositions comprising spermidine for the treatment of the stress urinary incontinence in a female subject. The inventive compositions are conceived either for transvaginal application to release spermidine onto external sphincter, urethra and endopelvic fascia, or for intravescial instillation. A variant composition takes the form of a condom lubricant comprising spermidine for the local release thereof during sexual intercourse, being an alternative or complementary to the local self-administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2833878A1
Jurisdiction
EP
Classification
—
Expires
2015-02-11
Drug substance claim
No
Drug product claim
No
Assignee
TIXUPHARMA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.